Should you buy Inovio Pharmaceuticals stock now?
No, the technical signal for Inovio Pharmaceuticals is currently SELL. Inovio Pharmaceuticals trades at $0.67 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.122 with falling momentum (signal: -0.080); RSI is at 25.0 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $2.77 points to 314.4% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Inovio Pharmaceuticals stock?
The average analyst price target for Inovio Pharmaceuticals is $2.77. The current price is $0.67, which gives an upside of 314.4%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $2.49 and $3.05.
Is Inovio Pharmaceuticals a dividend stock?
No, Inovio Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals is rated as a stock with extreme risk. the annual standard deviation is 87.1%, which classifies the stock as extreme risk. In addition, an RSI of 25.0 signals oversold (potential bottom).
Is Inovio Pharmaceuticals overvalued?
No, Inovio Pharmaceuticals is considered undervalued based on the analyst price target (314.4% upside). Inovio Pharmaceuticals has the following valuation ratios: a P/S ratio of 961.5, a P/B ratio of 11.3. The analyst price target suggests that the stock is undervalued by 314.4%.
Is Inovio Pharmaceuticals overbought?
No, Inovio Pharmaceuticals is actually oversold with an RSI of 25.0 (below 30). The technical indicators show: RSI is at 25.0 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 32.3% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish). IMPORTANT: The stock is oversold in a downtrend. A low RSI in a downtrend is NOT a buy signal – the price can keep falling. Wait for a trend reversal before buying.
When is the next Inovio Pharmaceuticals earnings report?
Inovio Pharmaceuticals reports its next earnings on August 11, 2026. The stock currently trades at $0.67. The RSI is at 25.0, so the report can reinforce the current technical trend.
Is Inovio Pharmaceuticals shorted?
Yes, Inovio Pharmaceuticals is shorted with 20.2% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Inovio Pharmaceuticals stock?
No, insiders are not buying Inovio Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 8 sales. On a net basis, 103,114 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 258,097 $ sold. Active sellers include Sumner Michael John, Shea Jacqueline Elizabeth, KIES PETER and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Inovio Pharmaceuticals a good stock?
Based on our total score, Inovio Pharmaceuticals is rated as a disastrous stock with a total score of 4 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 4/100, Quality: 4/100, Momentum: 3/100. In addition: analysts see 314.4% upside to the price target; technical signal: Strong Sell. Whether Inovio Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Inovio Pharmaceuticals stock?
The outlook for Inovio Pharmaceuticals based on current data: the average analyst price target is $2.77 (+314.4%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/11/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Inovio Pharmaceuticals stock falling?
Inovio Pharmaceuticals is falling right now. The technical indicators show: the price is 32.3% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 20.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Inovio Pharmaceuticals go?
The average analyst price target for Inovio Pharmaceuticals is $2.77, which corresponds to a potential gain of 314.4% from the current price of $0.67. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Inovio Pharmaceuticals fall?
We lack enough history to give a specific floor for Inovio Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Inovio Pharmaceuticals do?
Inovio Pharmaceuticals udvikler DNA-medicin, primært til behandling af HPV-relaterede sygdomme, kræft og infektioner. De tjener penge på at forske i og sælge disse DNA-lægemidler, som de laver med deres SynCon teknologi. For at få medicinen ind i kroppen bruger de deres CELLEC... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Inovio Pharmaceuticals as an investment.
Did Inovio Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Inovio Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Inovio Pharmaceuticals making money or losing money?
We have no current profitability data for Inovio Pharmaceuticals. See the latest report in the earnings history above.
Can Inovio Pharmaceuticals go bankrupt?
The bankruptcy risk of Inovio Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -131.29 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 65% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Inovio Pharmaceuticals have a lot of debt?
No, Inovio Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 65%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
